A nasal spray with a unique mode of action could serve patients with dry eye disease who cannot effectively use or who may not want to use eye drops, according to Francis S. Mah, MD.
Oyster Point Pharma’s OC-01 nasal spray is a selective nicotinic acetylcholine receptor agonist, which met its primary endpoint of increased Schirmer’s score in the ONSET-2 phase 3 trial.
“It is novel in terms of its mechanisms. It’s not an anti-inflammatory or something that is immunomodulatory in general. It’s stimulating nerve fibers. It’s activating real tears, (Read more...)